Alluvi Retatrutide 20mg Pen – Triple Agonist Research Compound

The Alluvi Retatrutide 20mg Pen is a precision-formulated investigational peptide device developed for laboratory and metabolic research applications. This prefilled pen contains Retatrutide, a triple agonist compound studied in GLP-1, GIP and glucagon receptor pathways.

Each pen delivers a total peptide content of 20mg in a stabilised solution format designed for controlled and repeatable research administration. The convenient pen system removes the need for reconstitution while supporting accurate dose selection.

Key Features

• 20mg total Retatrutide peptide content
• Triple agonist investigational compound
• GLP-1, GIP and glucagon receptor research
• Prefilled pen with 4 x 5mg dosing format
• No reconstitution required
• Precision dosing delivery system
• Manufactured by Alluvi Healthcare

How to Use

• Attach a sterile compatible needle before use
• Prime according to package instructions if required
• Select the desired dose for research protocol
• Administer via subcutaneous route where applicable
• Store refrigerated between 2–8°C

How It Works

• Retatrutide is investigated for triple receptor pathway activity
• Research focuses on GLP-1, GIP and glucagon receptor mechanisms
• The pen format supports convenient laboratory administration
• Precision dosing allows controlled investigational use

Recommended Research Pairings

• May complement broader metabolic investigation protocols
• Often researched alongside peptide and hormonal frameworks
• Can be included within advanced laboratory peptide studies